

PHARMACY FORMULARY UPDATES EFFECTIVE 8/1/2018

MVP Health Care's Pharmacy & Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require **prior authorization** for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at www.mvphealthcare.com

New Drugs (prior authorization required)

Drug Name	Indication	Commercial & Marketplace Tier	Medicare Part D Tier	MVP Medicaid
Crysvita	Pediatric and adult XLH	Medical	Non-formulary	Medical
Jynarque	ADPKD	Tier 3	Tier 5	Non-formulary
Tavalisse	ITP	Tier 3	Non-formulary	Non-formulary
Retacrit	Anemia	Tier 3	Non-formulary	Non-formulary
Aimovig	Migraine prevention	Tier 3	Non-formulary	Non-formulary
Lucemyra	Opioid withdrawal	Tier 3	Non-formulary	Non-formulary
Yonsa	Metastatic CRPC	Tier 3	Non-formulary	Non-formulary
Doptelet	Thrombocytopenia	Tier 3	Non-formulary	Non-formulary
Palynziq	Phenylketonuria	Tier 3	Non-formulary	Non-formulary
Balcoltra	Oral contraceptive	Tier 3	Non-formulary	Non-formulary
Osmolex	Parkinson's Disease	Tier 3	Non-formulary	Non-formulary
Akynzeo INJ	Chemotherapy NV	Medical	Non-formulary	Medical
Baclofen 5mg	Spasticity from MS	Tier 3	Non-formulary	Non-formulary
Dexycu	Post-op inflammation	Medical	Non-formulary	Medical
Goprelto	Nasal cavity surgery	Medical	Non-formulary	Medical

For Commercial & Exchange (non-Medicare) business:

Formulary additions/changes	
Drug Name	Tier
praziquantel	1(Tier 2 Exchange)
colesevelam	1(Tier 2 Exchange)
phytonadione	1

Drugs removed from PA for Commercial & Exchange business:

Symproic	Verzenio	Baxdela TABLETS	Trelegy Ellipta	Fiasp
Endari				

*May be covered under Part B if administered in the office or outpatient setting.
Therapy QL-Quantity Limits apply

M- Medical benefit + Step

If you have any questions with respect to this notice, please contact your Professional Relations Representative.

